Guselkumab for the treatment of psoriasis – evidence to date

• Main Authors: Miguel Nogueira, Tiago Torres
• Format: Article
• Language: English
• Published: BioExcel Publishing Ltd 2019-07-01
• Series: Drugs in Context
• Subjects: antibodies; biological products; interleukin-23; monoclonal; psoriasis
• Online Access: https://www.drugsincontext.com/guselkumab-for-the-treatment-of-psoriasis-evidence-to-date/

Psoriasis is a chronic, immune-mediated, inflammatory, and debilitating skin disease with significant impact on patients’ quality of life. Its pathogenesis is complex and not yet fully understood. However, the IL-23/IL-17 axis is currently considered the main pathogenic pathway in psoriasis. Guselkumab is a fully human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that binds to the p19 subunit of IL-23. It is the first of its class, already approved by the US Food and Drug Administration (FDA), as well as the European Medicines Agency (EMA) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for either systemic therapy or phototherapy. Several clinical trials have demonstrated potential benefits of guselkumab over other already approved immunomodulators in terms of safety and efficacy. The results of the head-to-head trial ECLIPSE were recently released and are addressed in this review. They contribute to the increasing confidence in guselkumab, demonstrating great potential for long-term treatment of psoriasis. However, further long-term data and additional comparative studies will be essential for positioning guselkumab in the therapeutic armamentarium for psoriasis.